MTOR and renal cell adenocarcinoma: Since Slattery et al. [13] first reported a positive association between mTOR rs1057079 and colon cancer risk in 2010, clinical evidence has accumulated regarding the relationship between mTOR SNPs and the risk of various cancers, such as gastric cancer [14-18], esophageal carcinoma [19, 20], endometrial cancer [21], renal cell cancer [10, 22], acute leukemia [23, 24], and colorectal cancer [25].